Skip to content

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04731701
Acronym
Hemo-FAST
Enrollment
180
Registered
2021-02-01
Start date
2021-05-05
Completion date
2022-07-19
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A, Hemophilia B

Brief summary

The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported functional mobility.

Detailed description

The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported functional mobility for adult haemophilia patients.

Interventions

DIAGNOSTIC_TESTHemophilia Joint Health Score (HJHS)

Joint examination with Hemophilia Joint Health Score (HJHS)

Sponsors

Kantar Health
CollaboratorINDUSTRY
Cerner Enviza (former Kantar Health)
CollaboratorUNKNOWN
Swedish Orphan Biovitrum
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

A patient must fulfil the following criteria in order to be included in the study: 1. Age ≥18 years. 2. Diagnosis of haemophilia A or B. 3. Capable of completing the study Patient-Reported Outcome (PRO) questionnaires in French. 4. Signed informed consent.

Exclusion criteria

The presence of any of the following criteria will exclude a patient from inclusion in the study: 1. Joint replacement within last 6 months. 2. Patients with a non-resolved joint or muscle bleeding event at the enrolment visit or ≤ 7 days prior to the enrolment visit. 3. Patients with comorbid illnesses such as juvenile arthritis, muscular dystrophy, neurologic illness/cognitive impairment, or other illnesses that may independently affect HJHS and Hemo-FAST scores and/or limit the ability of the patient to participate in the study as determined by the investigator.

Design outcomes

Primary

MeasureTime frameDescription
Psychometric validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).BaselineStatistical analysis to confirm the psychometric validation of the Hemo-FAST questionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026